Results 41 to 50 of about 520,129 (244)

Two rare complications in a single patient of lung cancer: Radiation-induced spontaneous esophageal perforation and aortic rupture and their successful management

Annals of Thoracic Medicine, 2019
Adjuvant radiotherapy is indicated in few operated cases of lung cancer for effective local control. Oesophageal perforation and aortic rupture are rare and lethal complications of postoperative adjuvant radiotherapy. Both of these complications happened
Mohan Venkatesh Pulle, Harsh Vardhan Puri, Belal Bin Asaf, Arvind Kumar   +3 more
doaj   +1 more source

Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy

Molecular Oncology, EarlyView.
We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen, Zhi Zhao, Henrik Horndalsveen, Maria Moksnes Bjaanæs, Bjørn Henning Grønberg, Tarje Halvorsen, Tesfaye Madebo, Marianne Aanerud, Jussi Koivunen, Kersti Oselin, Saulius Cicenas, Nina Helbekkmo, Jarkko Ahvonen, Maria Silvoniemi, Tine Norman Alver, Tonje Dalen, Åsa Kristina Öjlert, Saima Jamil Farooqi, Åslaug Helland, Vilde Drageset Haakensen   +19 more
wiley   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Risk of cardiovascular-related death after radiotherapy for thoracic cancer

Radiation Oncology
Cardiotoxicity following thoracic radiotherapy remains a critical issue, and this study aimed to assess the risk of Cardiovascular-Related Death (CVRD) after thoracic radiotherapy while comparing the risk of CVRD at different cancer sites.
Zhaoyuan Zhang, Dunchen Yao, Rong Jiang, Na Li, Wen Xiao, Yannan Zheng, Jiao Zhou, Yongqin Yang, Tianwang Guan, Zhigang Liu   +9 more
doaj   +1 more source

Inhalable ROS‐Responsive Nanospray Activates PPAR‐γ to Restore Macrophage Mitochondrial Homeostasis and Attenuate Radiation‐Induced Lung Injury

Advanced Science, EarlyView.
A nebulized nanoassembly alleviates radiation‐induced lung injury by reprogramming macrophages through coordinated ROS scavenging, NAD+ replenishment, and PPAR‐γ activation. Redox balance, mitochondrial homeostasis, and immune regulation are restored, revealing a microenvironment‐centered strategy for localized radioprotection.
Mingquan Gao, Xudong Yu, Ziqian Shang, Mengyao Tan, Xie Huang, Zaizhi Du, Xiaojiao Wang, Xinrui Yang, Ximei Luo, Weidong Wang, Rong Li, Shenglin Luo   +11 more
wiley   +1 more source

Fibrillarin Resists Cellular Senescence Via SIRT1‐Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
FBL directly binds to and stabilizes SIRT1 by blocking its ubiquitin‐proteasome degradation, thereby sustaining nicotinamide metabolism and redox homeostasis to counteract cellular senescence in ESCC. Genetic and pharmacological suppression of FBL sensitizes tumor cells to senolytic therapy.
Xing Jin, Hong Liu, Ling Gao, Lei Liu, Ji‐Bin Liu, Xiaoxia Jin, Ming‐Song Wang, Dan Liu, Li Feng, Wen‐Lian Chen   +9 more
wiley   +1 more source

A dynamic nomogram predicting symptomatic pneumonia in patients with lung cancer receiving thoracic radiation

BMC Pulmonary Medicine
Purpose The most common and potentially fatal side effect of thoracic radiation therapy is radiation pneumonitis (RP). Due to the lack of effective treatments, predicting radiation pneumonitis is crucial. This study aimed to develop a dynamic nomogram to
Yawen Zha, Jingjing Zhang, Xinyu Yan, Chen Yang, Lei Wen, Minying Li   +5 more
doaj   +1 more source

BraMARS: An Interpretable Histopathology‐Driven Deep Learning Model for Brain Metastasis Risk Stratification in Surgically Resected Limited‐Stage SCLC

Advanced Science, EarlyView.
This study presents BraMARS, an explainable deep learning model that estimates future brain metastasis risk in surgically resected limited‐stage small‐cell lung cancer using routine H&E‐stained whole‐slide images. By linking model‐attributed spatial histopathology with clinical outcomes and proteomic programs, BraMARS provides a biologically ...
Zijian Yang, Taolue Wang, Shilong Liu, Zicheng Zhang, Yibo Zhang, Fan Yang, Bo Yu, Shuaishuai Gao, Yu Chen, Lin Yang, Meng Zhou   +10 more
wiley   +1 more source

Effect of replanning boost radiotherapy plan in locally advanced unresectable middle to lower thoracic esophageal cancer

Scientific Reports
Thoracic bulky esophageal cancer shrinks during radiotherapy, changing the location and shape of the surrounding heart and lungs. The current study aimed to explore how replanning by volumetric-modulated arc radiotherapy (VMAT) and three-dimensional ...
Hiroyuki Inoo, Katsuyuki Sakanaka, Takashi Mizowaki   +2 more
doaj   +1 more source

Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?

Clinical Medicine Insights: Oncology, 2022
Background: The time interval between palliative thoracic radiotherapy and bevacizumab treatment strongly influences the frequency of adverse events (AEs) when both are concurrently applied to patients with advanced lung cancer.
Weigang Xiu, Xiaotong Guo, Min Yu, Yanying Li, Yong Xu, Jiang Zhu, Jingjing Luo   +6 more
doaj   +1 more source